Drugs that contain Belumosudil Mesylate

1. Drug name - REZUROCK

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8357693 KADMON PHARMS LLC Pharmacokinetically improved compounds
Oct, 2029

(7 years from now)

CN101208094A KADMON PHARMS LLC Pharmacokinetic Improved Compounds
Mar, 2026

(3 years from now)

CN101208094B KADMON PHARMS LLC Improved Pharmacokinetics Of Compound
Mar, 2026

(3 years from now)

IN200707965P1 KADMON PHARMS LLC Pharmacokinetically Improved Compounds
Mar, 2026

(3 years from now)

IN291914B KADMON PHARMS LLC Pharmacokinetically Improved Compounds
Mar, 2026

(3 years from now)

EP1865958A4 KADMON PHARMS LLC Pharmacokinetically Improved Compounds
Mar, 2026

(3 years from now)

EP1865958B1 KADMON PHARMS LLC Pharmacokinetically Improved Compounds
Mar, 2026

(3 years from now)

EP1865958A2 KADMON PHARMS LLC Pharmacokinetically Improved Compounds
Mar, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10696660 KADMON PHARMS LLC Rho kinase inhibitors Oct, 2033

(11 years from now)

US10183931 KADMON PHARMS LLC Rho kinase inhibitors Oct, 2033

(11 years from now)

US9815820 KADMON PHARMS LLC Rho kinase inhibitors Oct, 2033

(11 years from now)

Treatment: For the treatment of chronic graft versus host disease; For the treatment of chronic graft versus hold disease

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 200MG BASE TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.